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Abstract
Introduction: Assessment of  incidence and factors associated with late vs. early human immunode-
ficiency virus (HIV) diagnosis among newly diagnosed patients referred to HIV treatment centres in 
Poland in the years 2006-2008.
Material and methods: Retrospective analysis of medical records of patients reported from eight re-
gional centres for HIV treatment in Poland in years 2006-2008 was conducted. The study popula-
tion consisted of 1132 HIV-infected patients newly diagnosed with HIV infection, aged 17 years up.  
To describe characteristics of this group of patients in terms of clinical and immunological presenta-
tion multivariate regression analysis of demographic and epidemiology data including: sex, age, mode 
of transmission, CD4 T cell count, and viral load at the time of diagnosis was performed.
Results: Among 1132 patients included in the study 564 (49.8%) were late presenters (LP) according to 
European consensus definition. In multivariate logistic analysis including sex, age and route of infection, 
as independent factors, age (OR = 1.06), intravenous drug use (OR = 2.17 for IVDU vs. MSM), and 
heterosexuality (OR = 2.07 for Hx vs. MSM) were risk factors for late testing. The same factors were pre-
dictors of advanced HIV disease, as well as unknown route of infection (OR = 1.77; p < 0.05). However, 
multivariate regression analysis revealed that only advanced age was an independent factor influencing 
lower CD4 T cell count and late presentation (OR = 1.02 per 1 year of age, p < 0.001). 
Conclusions: Nearly 50% of patients were diagnosed after the optimal time for antiretroviral treat-
ment initiation, according to actual European and Polish guidelines. These results strongly point out 
the necessity of further encouragement toward more frequent and earlier HIV testing.
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Introduction
Despite more than three decades of the human immuno-
deficiency virus (HIV) epidemic and enormous progress in 
the treatment of the infection with common access to the high-
ly effective antiretroviral treatment, almost a third of individ-
uals infected with HIV enter a  health care system very late 
in the course of  their HIV infection throughout Central and 
Eastern Europe [1]. This situation has remained unchanged 
for the last several years without evidence of improvement [2]. 
Surveillance to identify the exact extent of the problem remains 
insufficient across Europe.
Currently available highly active antiretroviral therapy 
(HAART) has dramatically improved the prognosis and sur-
vival of  HIV infected patients [3]. However, late HIV diag-
nosis, especially when acquired immune deficiency syndrome 
(AIDS) defining disease has occurred, constitutes a relevant 
problem for treatment and leads to individual suboptimal us-
age of HAART [4-6].
Furthermore, late presenters represent an ongoing and seri-
ous challenge to the control of the AIDS pandemic. In a global 
perspective, HIV late diagnosis perpetuates HIV pandemics, 
while about 50% of  new sexually transmitted infections are 
transmitted from persons with early phase of HIV disease [7]. 
HIV late diagnosis and presentation for care is estimated at 
about 15-38% of cases across the Europe [8], and this has se-
rious societal and economic consequences, despite access to 
universal insurance coverage for complex specialist care [9-11].
Moreover, in the past it was difficult to evaluate the ex-
tend of  this problem, as there were numerous and diverse 
definitions of late presentation during the evaluation of col-
lected data (Table 1).
Currently we share one universal definition and, every 
patient with CD4 T cell count < 350 cells/μl and/or AIDS 
defining illness (ADI) fulfils criteria for being recognised as 
“late presenter” according to current treatment guidelines 
for HIV infected adults [12].
Since 1985, when HIV diagnostics was introduced in Po-
land, the number of newly diagnosed cases of HIV disease 
and AIDS has kept on increasing, particularly in recent years 
[13, 14].
The problem of  late presentation was not widely ad-
dressed in Poland. The first Polish data that we present were 
collected from significant number of  Polish patients from 
different HIV clinics and hospitals in the period 2006-2008. 
Therefore, the aim of the present study was to determine 
the  frequency of  late presenters among newly diagnosed 
individuals in the years 2006-2008 using current “late pre-
sentation” definition, to compare frequencies of late presen-
tation according to previous definitions and to describe late 
presenters clinical and immunological characteristics.
Material and methods
The study population consisted of  1132 HIV-infected, 
Caucasian patients newly diagnosed with HIV infection, 
aged 17 years up, reported from eight regional centres for 
HIV treatment in Poland. 
Out of  11 centres, operating during the  study period 
in Poland and invited for the survey, four centres provided 
data for 2006 and 2007 (n = 563) and eight centres for 2008 
(n  =  591). Foreigners and immigrants as well as patients 
diagnosed elsewhere were not included. Duplicate records 
of  patients registered in two centres during the  analysis 
period were excluded, with only the  earlier record being 
taken into account. 
To evaluate whether the study group was representative 
of  the  HIV patient population nationwide, the  study data 
were compared with those registered by the National Health 
Institute for the same period, i.e. 2006 through 2008.
Data on demographic and epidemiology, including age, 
sex, mode of HIV transmission (injection drug user – IDUs, 
heterosexual contact  – Hx, male having sex with male  – 
MSM, unknown/other  – UNK), CD4 T cell count, serum 
viral load at the time of diagnosis, and the patient’s medical 
history were gathered and analysed.
In terms of the numerous definitions of “late presenta-
tion” available at the time of the study the data were initially 
analysed applying a different set of parameters for late pre-
sentation (Fig. 1).
Clinical categories A, B, and C, as data were collected and 
used in the period 2006-2008, were applied according to re-
vised classification system for HIV infection among adoles-
cents and adults from the year 1993 [15]. In addition, a group 
of persons with very late presentation and CD4 T cell count 
under 50 cells/µl were analysed. 
The appropriate statistical tests were applied for paramet-
ric and non-parametric data using Statistica 7.0 software, with 
p value under 0.05 considered as clinically significant. Tests 
used for demographic data included Fisher test, Kruskal-Wal-
lis test, Mann-Whitney U-test. Odds ratios were assessed for 
late presenting risk using as independent factors age, gender, 
route of infection (IDU, Hx, MSM, and unknown), and uni-
variate and multivariate analyses were performed. 
Results
In total 1132 medical records of newly diagnosed patients 
were identified. The  general characteristic of  this group is 
presented in Table 1. These patients represented 46% of all 
patients diagnosed with HIV in Poland during the analysis 
period. Two hundred and sixty-four persons were recorded 
in 2006, 290 persons in 2007, and 578 in 2008.
Male gender strongly dominated in the analysed group – 
911 out of 1132 patients (80.5%). Median age at HIV diagnosis 
was 31.3 (IQD 26.8-38.6) years; female patients were younger 
than male: 30 (IQD 24.6-36.3) and 32 (IQD 27.3-39.1) years, 
respectively, and the  difference was statistically significant 
(p < 0.001). With respect to the mode of HIV transmission, 
there were 262 (23.1%) current or previous IDUs, 498 (44%) 
MSM (including bisexual men) and 275 (24.3%) Hx persons. 
The route of HIV infection remained unknown for 97 (8.6%) 
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Table 1. Comparison of medium age, CD4 T cell count, and viral load between particular gender, mode of transmission, and 
late vs. non-late testers. Statistical significance assessed using Mann-Whitney U test
All groups
N
(%)
Age (years)
Median (IQD: Q25-Q75)
CD4 (cells/μl) 
Median (IQD: Q25-Q75)
VL (copies/ml)
Median (IQD: Q25-Q75)
1132 31.3 (26.8-38.6) 355 (171-530) 30300 (5260-110580)
Female 221 (19.5%) 30.5 (24.6-36.3) 305 (125-503) 19050 (2640-75250)
Male 911 (80.5%) 32 (27.3-39.1) 368 (185-533) 35000 (6020-117000)
p = 0.001 p = 0.02 p = 0.006
IDUs 262 (23.1%) 31.7 (27.7-38) 289 (90-504) 31713 (6017-106000)
MSM 498 (44%) 30.3 (26.1-36.4) 418 (265-576) 28555 (6278-103000)
Hx 275 (24.3%) 33 (26.8-41.9) 282 (125-453) 29650 (3890-115000)
UNK 97 (8.6%) 36 (24.6-36.3) 364 (120-472) 41494 (1456-142500)
MSM vs. Hx: p = 0.002 
MSM vs. IDUs: p = 0.002
IDUs and Hx vs. MSM: 
p < 0.001; IDU vs. Hx: NS 
NS 
Clinical category A 760 29.8 (25.4-36.5) 461 (348-615) 17950 (3840-77500)
Clinical category B 85 34.3 (29.0-39.9) 230 (134-310) 37100 (7240-124000)
Clinical category C 287 35.2 (30.0-43.9) 65 (22-158) 100000 (1456-142500)
C vs. A and B vs. A:  
p < 0.001; B vs. C: NS
C vs. B and C vs. A:  
p < 0.001
CD4 < 50 cells/μl 137 34.6 (30.4-42.5) 20 (10-31) 120000 (85000-520000)
CD4 > 50 cells/μl 995 30.9 (28.2-37.9) 398 (243-562) 23450 (4290-98000)
p < 0.001 p < 0.001
CD4 < 200 cells/μl 323 34.8 (30.3-43.9) 64 (23-135) 100000 (29800-323593)
CD4 > 200 cells/μl 809 30.0 (25.5-36.7) 452 (337-604) 17800 (4170-80800)
p < 0.001 p < 0.001
CD4 < 200 cells/μl + 
clinical category C
363 34.8 (30.0-43.6) 76 (28-160) 100000 (27093-279000)
Other (all without CD4  
< 200 + clinical category C)
769 29.8 (25.3-36.5) 462 (348-615) 17000 (3865-74300)
p < 0.001 p < 0.001
CD4 < 350 cells/μl 556 34.0 (29.4-41.6) 166 (51-266) 71750 (15609-191000)
CD4 > 350 cells/μl 576 29.8 (25.3-36.5) 526 (434-670) 13100 (3122-61200)
p < 0.001 p < 0.001
CD4 < 350 cells/μl + 
clinical category C
564 34.0 (29.4-41.5) 170 (52-170) 72200 (15609-191000)
Other (all without CD4  
< 350 + clinical category C)
568 29.0 (24.7-35.6) 529 (435-672) 13056 (3100-58400)
p < 0.001 p < 0.001
^NS – not statistically significant 
IDUs – injection drug user, MSM – male having sex with male, Hx – heterosexual contact , UNK – unknown/other
persons. MSMs were significantly younger than IDUs and 
Hxs (p = 0.002 for both). 
Median CD4 T cell count at diagnosis was 355 cells/µl 
(IQD 171-530) in the whole group. Female patients had 
significantly lower CD4 T cell count than male; 305 cells/µl 
(IQD 125-503) and 368 (IQD 185-533), respectively 
(p = 0.02). Median CD4 T cell counts did not differ statis-
tically between IDUs and Hxs; 289 (125-453) and 282 (125-
453) cells/µl, respectively, but they were significantly higher 
in MSM – 418 (265-576) cells/µl than in both other groups 
(p < 0.001 for both). Among IDUs, male patients had signifi-
cantly lower CD4 T cell count (276 cells/µl) than female ones 
(349 cells/µl) from this group (p < 0.05).
Depending on the definition of “late presentation”, the in-
cidences for the whole group varied from about 25% when 
the  category C was defined to nearly 50% when the  most 
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recent definition was applied (Table 2). This describes late 
presentation as CD4 T cell count below 350 cells/µl and/or 
clinical CDC category C (AIDS-defining disease diagnosed) 
(Table 2). 
According to the current definition, the groups with 
the  highest rate of  late presentation were IDUs (59.2%) 
and Hxs (60.7%). Late presentation was also more frequent 
among female patients (55%) than among males (48%). 
In addition, 12% of  “very late testers” were identified. 
These were persons with CD4 T cell count under 50 cell/µl 
at HIV diagnosis. In the IDU group the frequency of “very 
late testers” was 17% while that among persons infected via 
the heterosexual route was 15.3% and for MSM it was 7.4%. 
The  frequency of  very late presenting females was 15.3% 
while for males it was 11.3%. Statistically significant differ-
ences in the  frequencies were found for all late presenting 
definitions between groups of IVDUs and heterosexually in-
fected persons vs. MSM (p < 0.05 for all comparisons). 
Patients diagnosed with clinical category A  were sig-
nificantly younger (median 29.8; IQD 25.4-36.5 years) than 
those with categories B and C (median 34.3, IQD 29-39.9 
years and 35.2, IQD 30-43.9 years), respectively  – differ-
ences A  vs. B and A  vs. C were statistically significant, 
p  <  0.001. The  same tendency was observed for all “late 
presenter” definitions, and patients diagnosed late were 
significantly older than those who presented earlier for 
diagnosis Table 1.  
Data on HIV viral load was available for 792 out of 1132 
patients (70%). As was suspected, medium viral load was 
significantly higher in late presenting group of patients re-
gardless of definition (p < 0.05 for all) (Table 1). 
Age, higher viral load, intravenous drug use, and het-
erosexuality were all predictors of late presenting according 
to current definition: IDUs vs. MSM – OR (odds ratio) 2.17 
(95% CI: 1.6-3.0), Hx vs. MSM – OR 2.1 (95% CI: 1.5-2.0), age 
OR = 1.07 (95% CI: 1.05-1.08) for 1 year of age (p < 0.001 for 
all). For advanced stage of HIV disease (CD4 < 200 cells/µl 
and C category of disease) female sex was also a predictor 
(OR = 1.49, p = 0.01). Multivariate logistic analysis showed 
that age, heterosexuality and intravenous drug use were in-
dependent predictors of late presenting regardless of defini-
tion (Table 3). Additionally, for advanced HIV-disease and 
AIDS diagnosis (category C of HIV disease) unknown route 
of  infection was also a predictor. However multivariate re-
gression analysis revealed that elder age was an independent 
factor influencing lower CD4 T cell count and late presenta-
tion. Multivariate logistic analysis showed that age, hetero-
sexuality, and intravenous drug use are independent predic-
tors of late presenting regardless of definition (Table 3). 
In univariate analysis female sex, increased age, higher 
viral load, and intravenous drug use were risk factors for 
lower CD4 T cell counts (p = 0.02, p < 0.001, p < 0.001, 
p  =  0.005). However, the  multivariate regression analysis 
revealed that increased age was independently related to 
the lower CD4 T cell count (p < 0.001) in males with a histo-
ry of IDU (p = 0.003).
Discussion
Primarily, it is worth underlying the fact that in the pre-
sented study almost half of the patients were considered late 
presenters according to the European Late Presenter Con-
sensus Working Group. This recent universal European defi-
nition considers a person presenting with CD4 T cell count 
less than 350 cells/µl and/or AIDS defining event, regardless 
of CD4 T cell count as being a  late presenter, and an indi-
vidual with an advanced HIV disease as having CD4 T cell 
Figure 1. Different characteristics of analyzed population ac-
cording to accepted definition
100
75
50
25
0
[%
]
AIDS           < 200   < 200 and/or AIDS  < 350   < 350 and/or AIDS
Table 2. Frequencies of late testing in groups of different routes of infection and gender 
Definition 
All, n = 1132 
(%)
IDUs, n = 262 
(%)
MSM, n = 498 
(%)
Hx, n = 275 
(%)
Female, n = 221 
(%)
Male, n = 911 
(%)
< 50 137 (12.1) 45 (17.2) 37 (7.4) 43 (15.6) 34 (15.3) 103 (11.3)
Clinical category C 287 (25.4) 84 (32) 76 (15.3) 91 (33) 62 (28) 225 (24.7)
< 200 323 (28.5) 101 (38.5) 86 (21.6) 100 (36.4) 80 (36.2) 243 (26.7)
< 200 and/or category C 363 (32.1) 110 (42) 103 (20.7) 113 (41.1) 87 (39.4) 276 (30.3)
< 350 556 (49.1) 153 (58.3) 192 (38.6) 165 (60) 122 (55) 434 (47.6)
< 350 and/or category C 564 (49.8) 155 (59.2) 196 (39.4) 167 (60.7) 122 (55) 437 (48)
Late presenters Non-late presenters
74.6 71.5
67.9 50.9 50.2
25.4 28.5
32.1
49.1 49.8
IDUs – injection drug user, MSM – male having sex with male, Hx – heterosexual contact
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count below 200 and/or AIDS-defining event regardless 
of CD4 T cell count [12].
Thus, we are facing a situation where half of the newly 
diagnosed patients in the years 2006-2008 were not able to 
fully profit from HAART, as recommended by European and 
Polish guidelines for treatment [16, 17]. 
Furthermore, these data are similar to those obtained 
from other European countries, most often applying 
the  200 cells/µl threshold as a  definition of  later presenta-
tion. For example, a  large Swiss cohort study revealed that 
about 30% of  patients diagnosed with CD4 T cell count be-
low 200 cells/µl and even 10% with below 50 cells/µl [18]. 
The factors associated with late diagnosis in the Swiss study 
were increased age and non-Caucasian race, in line with 
observations from northern France and Brussels, Belgium 
[19]. The second factor with its potential implication can be 
excluded in regard of  the  presented population since only 
the Caucasian patients were evaluated. Polish society is rela-
tively homogenic, so single cases of non-Caucasian and for-
eign patients were excluded from the analysis. Italian data 
from Modena show 39% late presenters among individuals 
diagnosed between 1992 to 2006 without a tendency to de-
crease [20]. In a Barcelona survey, independent risk factors 
for 56% of late presenters were increased age, heterosexual 
male gender, intravenous drug use, and being born in South 
America or sub-Saharan Africa [21]. United Kingdom re-
searchers observed a  higher percentage (48%) of  late pre-
senters among people aged 50 years and over compared with 
33% among younger individuals [22]. Reports from Croatia 
and Denmark concur with our observation that a  signifi-
cantly higher proportion of heterosexual patients than ho-
mosexuals are late presenters [23, 24].  
At the start of  the HIV epidemic in Poland, it was clear 
that injecting-drug-users were driving the  spread of  illness. 
A group of the highest risk of infection was the group of IDUs. 
Nowadays the  incidence of HIV acquisition by using drugs 
intravenously has decreased significantly. This change has tak-
en place due to the implementation of harm-reduction pro-
grams such as needle and syringe exchange or free needle and 
syringe distribution and opiate substitution programs, e.g. 
methadone programs [25]. It seems worth noting that types 
of drugs were also changed during the past few years, from 
domination of “homemade” heroin to usually oral drugs. 
However, with the  successful needle and syringe ex-
change programs, most transmissions have shifted to being 
sexual (between men, and men and women partners). It is 
important to develop a  clear understanding of  the  tested 
data and methods, and to constantly monitor the  changes 
or trends in these results in order to make significant prog-
ress. Becoming familiar with the characteristics of  the  late 
presenters is essential, given that among heterosexuals, 
the perception of the risk of HIV disease is known to be low. 
This information can be used to assess the  successfulness 
of health education campaigns. 
Secondly, it is worth pointing out that in the presented 
study men who have sex with men were diagnosed earlier 
than persons infected via heterosexual contacts or via intra-
venous drug usage. This appears to be that the group of MSM 
test themselves more often and HIV infection has thus been 
more frequently diagnosed before HIV disease progression. 
Therefore, the common opinion of homosexuals as being 
the highest risk group of HIV infection contributes to more 
frequent testing. The risk perception of heterosexuals seems 
to be lower, resulting in less frequent testing. This means that 
groups classically considered as having a  low-risk of  HIV 
might be of high risk of both HIV infection and late presen-
tation. However, unlike “safe sex” practices, frequent testing 
is not a HIV preventive measure.
Table 3. Multivariate analysis of factors influencing late presentation for different definitions of late presenters
n
Age#
(95% CI, p)
Female vs. male 
(95% CI, p)
IDUs vs. MSM  
(95% CI, p)
Hx vs. MSM 
(95% CI, p)
UNK vs. MSM
(95% CI, p)
All 1132
OR for CD4 < 50 cells/μl 137
1.04 (1.02-1.06, 
p = 0.000005)
1.15 (0.71-1.86, 
p = 0.56)
2.44 (1.5-3.97, 
p = 0.0003)
1.87 (1.1-3.19, 
p = 0.02)
1.37 (0.67-2.8, 
p = 0.38)
OR for C category  
of HIV infection
287
1.06 (1.04-1.07, 
p = 0.000000)
0.89 (0.6-1.3,  
p = 0.54)
2.72 (1.87-3.97, 
p = 0.000000)
2.55 (1.7-3.83, 
p = 0.000007)
2.69 (1.62-4.45, 
p = 0.0001)
OR for CD4 < 200 cells/μl 323
1.06 (1.05-1.08, 
p = 0.000000)
1.26 (0.87-1.83, 
p = 0.23)
2.83 (1.97-4.06, 
p = 0.000000)
2.16 (1.42-3.15, 
p = 0.0002)
2.13 (1.3-3.52, 
p = 0.003)
OR for CD4 < 200 cells/μl 
+ C category
363
1.06 (1.05-1.08, 
p = 0.000000)
1.19 (0.82-1.72, 
p = 0.35)
2.64 (1.86-3.75, 
p = 0.000000)
2.13 (1.45-3.13, 
p = 0.0001)
1.77 (1.08-2.9, 
p = 0.02)
OR for CD4 < 350 cells/μl 556
1.06 (1.05-1.08, 
p = 0.00000)
1.04 (0.73-1.5, 
p = 0.82)
2.15 (1.55-2.99, 
p = 0.000005)
2.07 (1.44-2.98, 
p = 0.000096)
1.08 (0.68-1.72, 
p = 0.75)
OR for CD4 < 350 cells/μl 
+ C category
564
1.07 (1.05-1.08, 
p = 0.000000)
1.004 (0.7-1.45, 
p = 0.99)
2.17 (1.56-3.02, 
p = 0.000004)
2.1 (1.45-2.03, 
p = 0.000078)
1.03 (0.7-1.45, 
p = 0.9)
#OR – per year 
IDUs – injection drug user, MSM – male having sex with male, Hx – heterosexual contact, UNK – unknown/other
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Late presenters are more likely than early presenters to be 
diagnosed with opportunistic infections, their risk of death is 
higher, and their rate of immunological improvement is slow-
er [26, 27]. Initiation of HAART at higher CD4 T cell counts 
is associated with a  lower frequency of  antiretroviral drug 
resistance mutations at virological failure [28]. Late presenta-
tion (CD4 < 350 cells/μl) was found to be related with signifi-
cantly higher costs, especially inpatient costs during the first 
year of medical care, and two-fold higher costs were observed 
during further treatment compared to patients presenting 
with CD4 T cell counts above 350 cells/μl [11].
Moreover, ignorance of the serological status means that 
late presenters are likely to transmit the virus [29]. However, 
to present for testing requires the perception of being at risk 
of those potentially infected and a higher level of suspicion 
among clinicians of all specialties [30]. 
So far, several barriers impairing HIV testing have been 
identified, both among patients and health care providers 
[31-33]. Among the  most important of  these barriers in 
Poland are perception of  low or no risk, fear of disclosure 
among patients (HIV stigma), and lack of  knowledge and 
self-confidence among health care providers when propos-
ing HIV testing. Therefore, it is very difficult to establish 
the  “dark figure”, the  actual number of  currently undiag-
nosed HIV positive individuals in our country.
Late presentation of HIV infected persons for care seems 
to be a universal problem in Europe [4], despite significant 
and constant progress in health care. Therefore, HIV testing 
policies and practices should be thoroughly analysed, adapt-
ed to local conditions, and subsequently implemented. To 
realise these goals the “HIV in Europe Initiative” was started. 
In view of  the  public health implications of  early HIV di-
agnosis for reducing HIV transmission and preventing late 
presentation, HIV testing should be more frequently offered 
in all health care settings.
The most important issue is to find an answer to the ques-
tion: Who is the person with the highest risk of presenting 
late?
Therefore, nowadays it is believed that the key element in 
the control of the HIV epidemic is the optimisation of test-
ing for HIV. It is worth emphasising that carried-out studies 
like the  European project HIDES 1 and 2 (HIV Indicator 
Disease Across Europe Study) have shown that the  testing 
model based on the routine indicator condition-guided HIV 
testing, the prevalence of which in the population amounts 
to > 0.1%, is very effective [34, 35].
Since May 2015 at the Emergency Department of the Hos-
pital for Infectious Diseases in Warsaw a modern testing strat-
egy based on the  indicator conditions like mononucleosis- 
like syndrome and pneumonia has started, surprisingly this 
method of testing is extremely effective, and it might be a fu-
ture solution on how to diagnose at an early stage of the HIV 
infection.
On the basis of the presented study it seems that the most 
important task for the future seems to be the matter of rais-
ing people’s awareness of risky behaviours. Education should 
be provided beginning as early as it is possible, i.e. prior to 
having any possibly risky contacts. Furthermore, efforts are 
needed to encourage HIV testing among groups not tradi-
tionally perceived as high-risk. 
Nowadays, in the  Department for Adults Infectious 
Diseases of Medical University of Warsaw and Out-Patient 
Clinic of  the  Hospital for Infectious Diseases in Warsaw, 
the  realisation of  a subsequent scientific project, aimed at 
the evaluation of a percentage of late presenters among pa-
tients with the HIV admitted to this unit in recent years, was 
commenced. 
It should be noted that the characteristics of this group 
of persons will most likely enable the introduction of effec-
tive methods aimed at the said group of persons in the fu-
ture. It seems to be clear that the awareness of transmission 
trends lets us find and understand an effective way to reach 
the groups at the highest risk of late presentation.
Conclusions
1. Almost 50% of patients were diagnosed late, after the op-
timal time to start HAART, in the  years 2006-2008 in 
Poland.
2. Increased age and being a  male intravenous drug user 
were risk factors for lower CD4 T cell count and late pre-
sentation.
3. MSMs were diagnosed much earlier in the course of HIV 
infection, but heterosexuals are at risk of late diagnosis 
and AIDS-defining disease occurrence.
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